Clinical implications of the intrinsic molecular subtypes of breast cancer - Wikidata - wikimedia - TriplyDB

Clinical implications of the intrinsic molecular subtypes of breast cancer

Clinical implications of the intrinsic molecular subtypes of breast cancer

http://www.wikidata.org/entity/Q26800996

about

Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting Molecular subtypes and imaging phenotypes of breast cancer.Breast cancer molecular subtypes: from TNBC to QNBC BI-RADS 3-5 microcalcifications can preoperatively predict breast cancer HER2 and Luminal a molecular subtype Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.Comprehensive comparison of molecular portraits between cell lines and tumors in breast cancer.Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.Androgen receptor expression predicts beneficial tamoxifen response in oestrogen receptor-α-negative breast cancer Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes.ONE-CLASS DETECTION OF CELL STATES IN TUMOR SUBTYPES Functional and prognostic significance of long non-coding RNA MALAT1 as a metastasis driver in ER negative lymph node negative breast cancer.Oestrogen receptor negativity in breast cancer: a cause or consequence?Luminal B breast cancer: patterns of recurrence and clinical outcome.Epidemiology and survival outcome of breast cancer in a nationwide study.Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.High expression of COX5B is associated with poor prognosis in breast cancer.Bevacizumab Modulation of the Interaction Between the MCF-7 Cell Line and the Chick Embryo Chorioallantoic Membrane.Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge.Hereditary breast and ovarian cancer: new genes in confined pathways.Expression Profiling of Clinical Specimens Supports the Existence of Neural Progenitor-Like Stem Cells in Basal Breast Cancers.Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer.FDG PET/CT Assesses the Risk of Femoral Pathological Fractures in Patients With Metastatic Breast Cancer.Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity.Wnt signaling in triple-negative breast cancer.Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer.MPZL1 forms a signalling complex with GRB2 adaptor and PTPN11 phosphatase in HER2-positive breast cancer cells Papillotubular carcinoma with an invasive micropapillary carcinoma component of the breast, characterized by a rapid increase in size due to intra-tumoral hemorrhage: A case report.Ancestry as a potential modifier of gene expression in breast tumors from Colombian women.Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer.A pathways-based prediction model for classifying breast cancer subtypes.Revisiting the impact of age and molecular subtype on overall survival after radiotherapy in breast cancer patients.Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.Genomic profiling of breast cancer in African-American women using MammaPrint.Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes.

P2860

Q26747792-A4A50222-B9AD-46D7-8CBF-5BBCB784E9F9 Q28069885-51D75B83-E777-42AD-87ED-23776CF30C82 Q28076805-4E533018-118E-44B8-8CD3-EC2A9BE6C0E0 Q30358627-F63494A1-61C8-49F1-9888-0BE18CFA9E73 Q33659361-23FA8ADE-D104-40C9-A3B0-A95BADE8B39B Q33706962-C7978786-F280-4A69-9ADC-E4ED3EE958C7 Q36110285-4B4A80D4-F82E-4121-99CC-9ECBDEC05955 Q36111215-901B293D-6355-48D9-B9D0-F4EAEAB7C143 Q36383626-3BB1957E-BCC5-4C77-9844-70F9526A8443 Q36547919-86AE9327-3EF0-4AE0-9D67-DCBF63B94AA5 Q36784065-23A8897F-3916-422A-8C7E-3ABE2A325869 Q36867680-29972DC3-CAD7-43A1-8D82-E372CBE29DF7 Q37457902-A420C3FC-99F2-477C-97CC-869C3CEC91C6 Q37529397-AB1ABB22-ECCB-4D45-BDC9-0C9641ED4D78 Q37662184-FB638805-8488-4B5E-A5EB-31CE0C793448 Q37725545-822C1864-060E-4B2E-B5BA-E0AD820C6EB5 Q38641240-D87761CB-AB7C-48CD-B32F-C9FC2E3514F1 Q38673586-2CE15384-2629-4080-8D57-A7923E9F4D80 Q38709589-733A0306-9E0D-4E21-B2AB-7480EB3B438C Q38747875-D0126CD3-0218-40DE-9806-A79A077BBF0E Q38786102-DC26575A-026A-4ED7-94BB-B2407D279EF2 Q38925408-8B30245D-369F-49AC-9429-81CA25F290DB Q38952768-1118A341-A0BA-418C-B96C-8D70AA26A558 Q39021766-7A9A11AE-7D79-4231-8DBD-8022C6F4A3AE Q39122509-F20B083D-F6C3-44AA-9C74-0059485833C4 Q39144794-C1FD21A5-8E12-442D-A1DB-9C1115D1186C Q39214992-7312744D-5784-4407-A6C7-C092D5E2A4DB Q39262474-CF248840-E8DF-4A7F-A5A7-AAE98F22CEB5 Q39625095-FF1391A4-D900-4C8E-910C-83CF70AC2DEC Q40053251-28EBF401-2399-4A93-942D-E455FFA886DB Q41050362-E14AA064-0281-435A-A6E5-04FCCB56BBD4 Q41235051-42D8F7DB-F034-4D4E-9208-77BF00A24982 Q41498719-AB687A2C-2944-49FD-B488-1D25FB82CCB7 Q41659344-BD6A99CF-073F-4FEC-9FEC-04199852946F Q41709107-90C9DDE5-B76B-4D7C-8BA1-9F55DD93F56C Q42282489-83A2C4B3-9794-4BC4-BD05-4D394F4CC309 Q42497114-5CD65408-F18C-4689-8C97-7FAAC73DC285 Q42498238-0B388C0E-18A8-4763-8C1B-5392CD718AE2 Q45134639-C6E9AED7-5D8B-4FC4-A3A5-01438430FB9E Q45933729-39113625-EEFF-4397-B95E-5816C6D7BC28

P2860

Clinical implications of the intrinsic molecular subtypes of breast cancer

http://www.wikidata.org/entity/Q26800996

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Clinical implications of the intrinsic molecular subtypes of breast cancer

@ast

Clinical implications of the intrinsic molecular subtypes of breast cancer

@en

Clinical implications of the intrinsic molecular subtypes of breast cancer

@nl

type

label

Clinical implications of the intrinsic molecular subtypes of breast cancer

@ast

Clinical implications of the intrinsic molecular subtypes of breast cancer

@en

Clinical implications of the intrinsic molecular subtypes of breast cancer

@nl

prefLabel

Clinical implications of the intrinsic molecular subtypes of breast cancer

@ast

Clinical implications of the intrinsic molecular subtypes of breast cancer

@en

Clinical implications of the intrinsic molecular subtypes of breast cancer

@nl

P1433

Q26800996-63D28AB9-7D9E-4AFC-A925-CC6225065A69

P1476

Q26800996-790FB586-0807-40CB-9043-239D43496594

P2093

Q26800996-1CEC2ED0-E252-43AE-905A-404EE08ABC36

Q26800996-2549187C-B5DF-435A-89ED-A73FC7248E77

Q26800996-379C0030-87B7-43EA-BDB4-9EC605EDD884

Q26800996-5557E5C8-E155-4794-8A3B-F732E3264333

Q26800996-91C45DCE-3BC1-4677-BDCD-13BCB1F18DD2

Q26800996-9CAA13F1-0564-4A57-BF78-A69876916982

Q26800996-A80BE04E-F70F-4467-BA94-EC8FB62E02CD

Q26800996-C4A01882-D1C5-4111-8CA9-F4AF0C0A477D

P304

Q26800996-F2B7705F-99DD-49C9-9D72-5A357BD9B0DB

P31

Q26800996-859007EA-B113-45C4-A20B-A2D8D8DD11CA

P3181

Q26800996-577F90BB-E084-467A-A8BA-0A1D8499B250

P356

Q26800996-60348AB0-C6F8-47CF-A35B-3B83D51C13D5

P407

Q26800996-7C2C1426-E0BB-4B7D-AE38-16FEA6AEB457

P478

Q26800996-EEC58C8F-9642-4DF1-AA0E-2F5F7B5B90EF

P50

Q26800996-6086C182-0E02-4322-910C-0F638D861EEB

Q26800996-78EEFF29-4443-434C-9137-596F3C1CD073

P577

Q26800996-4A39C30C-071C-447E-AA48-AE62004E04E1

P5875

Q26800996-4167B720-F273-4235-B452-670E77E3A85E

P698

Q26800996-222B9D74-77D8-475F-86E2-3D32C8967271

P3181

P356

J.BREAST.2015.07.008

P1433

P1476

Clinical implications of the intrinsic molecular subtypes of breast cancer

@en

P2093

Aleix Prat

http://www.w3.org/2001/XMLSchema#string

Barbara Adamo

http://www.w3.org/2001/XMLSchema#string

Estela Pineda

http://www.w3.org/2001/XMLSchema#string

Lydia Gaba

http://www.w3.org/2001/XMLSchema#string

Marc Díez

http://www.w3.org/2001/XMLSchema#string

Margarita Viladot

http://www.w3.org/2001/XMLSchema#string

Montserrat Muñoz

http://www.w3.org/2001/XMLSchema#string

Patricia Galván

http://www.w3.org/2001/XMLSchema#string

P304

S26-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

208712

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.BREAST.2015.07.008

http://www.w3.org/2001/XMLSchema#string

P407

P478

24 Suppl 2

http://www.w3.org/2001/XMLSchema#string

P50

A Fernandez-Martinez

P577

2015-08-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280866762

http://www.w3.org/2001/XMLSchema#string

P698

26253814

http://www.w3.org/2001/XMLSchema#string